Trial Profile
A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2020
Price :
$35
*
At a glance
- Drugs JKB 122 (Primary)
- Indications Autoimmune hepatitis
- Focus Therapeutic Use
- Acronyms JKB-122AIH
- Sponsors TaiwanJ Pharmaceuticals
- 21 Jan 2019 Results presented in a TaiwanJ Pharmaceuticals Media Release.
- 21 Jan 2019 Primary endpoint (Changes in ALT in AIH subjects given daily doses of JKB-122) has been met, according to a TaiwanJ Pharmaceuticals media release.
- 21 Jan 2019 Status changed from active, no longer recruiting to completed, according to a TaiwanJ Pharmaceuticals media release.